Know Cancer

or
forgot password

Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer


Phase 3
18 Years
70 Years
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer


Inclusion Criteria:



- Triple-negative breast cancer

- Older than 18 years old

- Have tumor resection surgery

- Sufficient organ function (marrow, heart, liver)

Exclusion Criteria:

- Other malignancy

- Other serious disease( marrow, heart, liver)

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Disease Free Survival (DFS) of 5 years

Outcome Description:

local recurrence, distant metastasis, the secondary primary malignancy

Outcome Time Frame:

5 years after mastectomy

Safety Issue:

No

Principal Investigator

Peng Yuan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Chinese Academy of Medical Sciences

Authority:

China: Ministry of Health

Study ID:

CH-BC-007

NCT ID:

NCT01150513

Start Date:

June 2010

Completion Date:

June 2020

Related Keywords:

  • Breast Cancer
  • TRIPLE-NEGATIVE
  • BREAST CANCER
  • Breast Neoplasms

Name

Location